^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD40HVac

    i
    Other names: CD40HVac, HPVDC injection, CD40.HVac, EDC.HPVE6E7
    Associations

    News

    Trials
    Company:
    LinKinVax
    Drug class:
    CD40 partial agonist
    Associations

    News

    Trials
    2ms
    HPVDCVax: Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial primary completion date
    |
    CD40HVac
    over2years
    HPVDCVax: Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New P1/2 trial • IO biomarker
    |
    CD69 (CD69 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CD40HVac